Skip to main content

Table 1 Patients’ characteristics

From: Influence of peritoneal carcinomatosis on perioperative outcome in palliative gastric bypass for malignant gastric outlet obstruction - a retrospective cohort study

 Overall cohort (n = 72)Peritoneal carcinomatosis vs. no peritoneal carcinomatosis (PC)
PC cohort (n = 39)No PC cohort (n = 33)p value
Demographics
 Sex, n (%)   .502
  Male38 (52.8)22 (56.4)16 (48.5) 
  Female34 (47.2)17 (43.6)17 (51.5) 
 Age (years)66 (58–74)66 (57–74)65 (59–74).591
 BMI (kg/m2)24 (21–26)23 (21–26)24 (21–27).635
 ASA, n (%)   .654
  I000 
  II19 (26.4)12 (30.8)7 (21.2) 
  III45 (62.5)23 (59.0)22 (66.7) 
  IV8 (11.1)4 (10.3)4 (12.1) 
  V0 0 
Tumor characteristics
 Primary tumor, n (%)   .324
  Pancreatic adenocarcinoma42 (58.3)18 (46.2)24 (72.7) 
  Cholangiocellular carcinoma10 (13.9)8 (20.5)2 (6.1) 
  Gastric adenocarcinoma5 (6.9)3 (7.7)2 (6,1) 
  Intestinal carcinoma3 (4.2)2 (5.1)1 (3.0) 
  Colorectal carcinoma6 (8.3)4 (10.3)2 (6.1) 
  Renal cell carcinoma2 (2.8)1 (2.6)1 (3.0) 
  Transitional cell carcinoma1 (1.4)1 (2.6)0 
  Mammarian carcinoma2 (2.8)2 (5.1)0 
  Ovarian cancer1 (1.4)01 (3.0) 
 Synchronous/metachronous PC, n (%)    
  Synchronous PCn.a.20 (51.3)n.a. 
  Metachronous PCn.a.19 (48.7)n.a. 
 Distant metastasis, n (%)   .132
  Yes24 (33.3)10 (25.6)14 (42.4) 
  No48 (66.7)29 (74.4)19 (57.6) 
 Preoperative chemotherapy, n (%)   .776
  Yes10 (13.9)5 (12.8)5 (15.2) 
  No62 (86.1)34 (87.2)28 (84.8) 
Clinical chemistry
 Sodium (mmol/l)139 (136–141)139 (136–142)138 (136–141).536
 Hemoglobin (g/dl)10.6 (9.3–12.1)11.2 (9.0–12.7)10.2 (9.4–11.7).235
 Platelet count (nl)242 (198–355)250 (201–341)215 (195–416).739
 Total bilirubin (mg/dl)0.6 (0.4–2.0)0.59 (0.37–1.42)0.76 (0.44–3.81).235
 Prothrombin time (%)87 (77–98)89 (76–98)85 (76–98).773
 INR1.1 (1.0–1.2)1.1 (1.0–1.2)1.1 (1.0–1.2).874
 Albumin (g/l)32 (29–39)34 (28–38)31 (28–39).394
 Creatinine (mg/dl)0.8 (0.6–1.0)0.9 (0.6–1.1)0.7 (0.6–0.9).230
 CRP (mg/l)29 (11–56)25 (8–51)31 (13–81).317
Operative data
 Laparoscopic surgery, n (%)2 (2.8)02 (6.1).119
 Concomitant hepaticojejunostomy, n (%)26 (36.1)10 (25.6)16 (48.5).044
 Operative procedure, n (%)   .831
  Antecolic approach6 (8.3)3 (7.7)3 (9.1) 
  Retrocolic approach66 (91.7)36 (92.3)30 (90.9) 
 Operation time (min)170 (128–214)160 (113–215)192 (150–216).124
 Intraoperative blood transfusion (U)000 (0–2).817
 Intraoperative fresh frozen plasma (U)000.108
Postoperative data
 Intensive care, days1 (0–2)1 (0–2)1 (0–3).240
 Hospitalization, days13 (9–18)13 (10–20)12 (9–17).392
 PBD*, n (%)6 (13.0)5 (17.2)1 (5.9).270
 Postoperative complications, n (%)   .381
  No complications23 (31.9)13 (33.3)10 (30.3) 
  Clavien-Dindo I8 (11.1)4 (10.3)4 (12.1) 
  Clavien-Dindo II20 (27.8)8 (20.5)12 (36.4) 
  Clavien-Dindo IIIa4 (5.6)2 (5.1)2 (6.1) 
  Clavien-Dindo IIIb5 (6.9)2 (5.1)3 (9.1) 
  Clavien-Dindo IVa1 (1.4)1 (2.6)0 
  Clavien-Dindo IVb000 
  Clavien-Dindo V11 (15.3)9 (23.1)2 (6.1) 
 In-house mortality, n (%)11 (15.3)9 (23.1)2 (6.1).046
 Anastomotic stenosis, n (%)2 (2.8)1 (2.6)1 (3).905
 Anastomotic leakage, n (%)2 (2.8)2 (5.1)0.187
 Delayed gastric emptying, n (%)18 (25.0)13 (33.3)5 (15.2).076
 Paralytic ileus, n (%)12 (16.7)9 (23.1)3 (9.1).113
 Pneumonia, n (%)11 (15.3)7 (17.9)4 (12.1).493
  1. Data presented as median and interquartile range if not noted otherwise. Categorical data were compared using the chi-squared test, Fisher’s exact test, or linear-by-linear association according to the scale and number of cases. Data derived from continuous variables of different groups were compared by the Mann-Whitney U test
  2. CRP c-reactive protein, INR international normalized ratio, PBD percutaneous biliary drainage, PC peritoneal carcinomatosis
  3. *Statistics are calculated for patients who did not undergo concomitant hepaticojejunostomy during the surgical procedure